Navigation Links
Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
Date:3/12/2008

WILMINGTON, Del., March 12, 2008 AstraZeneca (NYSE: AZN) announced today that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the companys investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC). The two studies ZODIAC (ZACTIMA in cOmbination with Docetaxel In non-smAll cell lung Cancer) and ZEAL (ZACTIMA Efficacy with Alimta in Lung cancer) are the second and third of four ongoing studies to complete enrollment. Data from the studies are expected later this year and the broad development program is on track for a first regulatory submission in 2008.

ZODIAC is a randomized, double-blind, international, multi-center Phase III study to assess the efficacy of vandetanib 100mg once-daily plus the standard docetaxel chemotherapy versus docetaxel alone in 1,380 patients with locally advanced or metastatic NSCLC after failure of first-line anti-cancer therapy.

ZEAL is a Phase III parallel group, randomized, double-blind study evaluating vandetanib 100mg once daily plus pemetrexed 500mg/m2 (every 3 weeks) compared with placebo plus pemetrexed as second-line treatment in 510 patients with locally advanced or metastatic NSCLC who have failed first-line anti-cancer therapy.

The ZEST study, which is investigating vandetanib versus erlotinib, was the first Phase III study of vandetanib to complete enrollment in November 2007.

NSCLC is an area of high unmet medical need, and we hope vandetanib will offer a beneficial new treatment option that may improve the lives of people with lung cancer, said Dr. Peter Langmuir, Medical Science Director at AstraZeneca.

ZODIAC and ZEAL are part of a broad Phase III clinical trial program designed to gain an understanding of how vandetanib may benefit people with lung cancer.

The other studies are:

  • ZEST (vandetanib versus erlotinib) enrollment is complete; and
    <
    '/>"/>

Contact: Asa Josefsson
asa.josefsson@astrazeneca.com
302-885-4109
Edelman Public Relations
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
2. New 2008 Health Plan Directory Features Year-End 2007 Enrollment Data and 4,600 Key Executives
3. Office of Administration Extends Retired State Employees Health Benefits Enrollment Period to March 21
4. Medicares Drug Program Enrollment Up, Costs Down
5. MedicareCRM(TM) Simplifies Annual Enrollment Period for Medicare Health Plans and Beneficiaries
6. Boosts in Managed Care Enrollment Seen Across The Board
7. Devax Announces Completion of Enrollment of DIVERGE Trial of Novel Drug- Eluting Stent System for Bifurcation Lesions
8. Blue Cross Stop Smoking Phone Coaching Enrollments Jumped in October
9. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
10. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
11. Medicare Rx Beneficiaries Urged to Review Changes to Their Drug Plans and Compare with Other Plans During Open Enrollment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... In the April issue of Experimental Biology ... by Drs. Rex Gaskins and Paul Kenis in ... campus of the University of Illinois Urbana-Champaign describe ... reduction-oxidation reactions underlie a variety of cell functions ... to these crucial roles in regulating normal cellular ...
(Date:4/17/2014)... Le Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, ... the April issue of Nature Reviews Microbiology ... Dr. McCullers, a world-renowned infectious disease specialist, ... the University of Tennessee Health Science Center, analyzed ... 1918, 1957 and 1968 pandemics, as well as ...
(Date:4/17/2014)... million older Americans suffer from depression, often brought on ... research a project that followed the lives of ... found that Internet use among the elderly can reduce ... , "That,s a very strong effect," said Shelia Cotten, ... and media who led the project. "And it all ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... stove instead of the traditional indoor open fire, experienced improved ... habit, according to a recent study. The study, ... project examining the impact of the use of vented stoves ... 1 issue of the American Journal of Respiratory and ...
... ... up with Zogby International to poll voters in competitive House and Senate 2010 elections ... may want to proceed with extreme caution on health care. , ... (PRWEB) September 22, 2009 -- Recently ...
... , , RADNOR, Pa., Sept. 22 The ... Topaz Kessler Meltzer & Check, LLP: , , ... in the United States District Court for the Eastern District of ... BLUD ) ("Immucor" or the "Company") between October 19, ...
... , , FLINT, Mich., Sept. 22 ... closer to receiving one of the most advanced forms of treatment ... and ProTom International, a Texas-based health care technology company. , ... Radiance 330 , combines the most ...
... SOUTHAMPTON, Pa., Sept. 22 Environmental Tectonics Corporation,s ... Systems today announced the sale of an additional BARA-MED((R)) ... , , Comprehensive Healthcare Solutions is ... operating wound healing institutes throughout the United States. This ...
... , , , Two ... , , Sixty-eight percent do not want ... , Sixty-three percent favor keeping conscience protection laws , ... the United States Conference of Catholic Bishops (USCCB) has found widespread public opposition ...
Cached Medicine News:Health News:New stove dramatically improves lung health in Mexican women 2Health News:New stove dramatically improves lung health in Mexican women 3Health News:Brad O'Leary: New Poll: Health Care Issues Loom Large for 2010 Elections 2Health News:Brad O'Leary: New Poll: Health Care Issues Loom Large for 2010 Elections 3Health News:Shareholder Class Action Filed Against Immucor, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP 2Health News:Shareholder Class Action Filed Against Immucor, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP 3Health News:McLaren Health Care Forming Partnership With ProTom International to Build First Proton Beam Therapy Center In Michigan 2Health News:McLaren Health Care Forming Partnership With ProTom International to Build First Proton Beam Therapy Center In Michigan 3Health News:McLaren Health Care Forming Partnership With ProTom International to Build First Proton Beam Therapy Center In Michigan 4Health News:Environmental Tectonics Corporation Places a BARA-MED(R) XD Monoplace Hyperbaric Chamber with Comprehensive Healthcare Solutions, Inc. 2Health News:Environmental Tectonics Corporation Places a BARA-MED(R) XD Monoplace Hyperbaric Chamber with Comprehensive Healthcare Solutions, Inc. 3Health News:Environmental Tectonics Corporation Places a BARA-MED(R) XD Monoplace Hyperbaric Chamber with Comprehensive Healthcare Solutions, Inc. 4Health News:New Survey: Most Americans Want Health Care Reform, Oppose Abortion Coverage, Support Conscience Protection Laws 2
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)... 15, 2014  In an unprecedented effort to curb the spread of ... other transport vehicles, an advanced and portable UV germicidal lamp manufactured ... first time. In order to prevent EMS paramedics ... West Palm Beach Fire Rescue is the ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... from a heart attack is more than a fear among people ... The mortality and morbidity rates for heart disease among those ... Ohio, according to federal and state data. But with ... that will soon change. The federal grant will be used to ...
... Mich., Oct. 6, 2011 Perrigo Company (Nasdaq: PRGO;TASE) ... Food and Drug Administration (FDA) for its Abbreviated New ... Perrigo believes it is first-to-file on this product. ... Pty. Ltd. filed a patent infringement suit in the ...
Cached Medicine Technology:Grant Will Help Save Lives in Appalachian Ohio 2Perrigo Company Confirms FDA Tentative Approval for Clobetasol Propionate Emulsion Foam 2
Designed to give maximum drying area while taking up minimal bench space....
Used to remove wrinkles from sections and for reorientating embedded tissue....
Compact instrument that quickly dries racks of slides using warm air....
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Medicine Products: